Epimmune, Anosys to merge

EPMN and cancer vaccine company Anosys (Menlo Park, Calif.) said they will merge in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys' exosome delivery technology and focus on immunotherapeutics to treat cancer and infectious diseases. The pipeline will include EPMN's HIV-1090, which is in Phase I/II studies to treat HIV, and Anosys' Dexosome-based cancer vaccine, which is in Phase II studies to treat melanoma and Phase I/II studies for non-small cell lung cancer (NSCLC). Poste merger, the company will be headquartered in San Diego, Calif., with manufacturing facilities in Menlo Park, Calif., and Evry, France. ...